MARKET

INCY

INCY

Incyte Corp
NASDAQ
120.16
-0.36
-0.30%
After Hours: 120.17 +0.01 +0.01% 19:40 08/14 EDT
OPEN
119.15
PREV CLOSE
120.52
HIGH
120.44
LOW
117.56
VOLUME
785.83K
TURNOVER
--
52 WEEK HIGH
132.60
52 WEEK LOW
78.20
MARKET CAP
24.36B
P/E (TTM)
15.31
1D
5D
1M
3M
1Y
5Y
1D
Top Incyte Executive Makes Major Move With Fresh Stock Sale
TipRanks · 1d ago
Incyte Earnings Call: Growth Surges, Costs Climb
TipRanks · 1d ago
Stock index futures largely flat after S&P 500 closes at record high
Seeking Alpha · 1d ago
Analysts Offer Insights on Healthcare Companies: HealthStream (HSTM), Incyte (INCY) and Hyperion DeFi (HYPD)
TipRanks · 2d ago
Incyte (INCY), What Is Behind The Latest Attention?
Simply Wall St · 3d ago
Regeneron, Tenet leads top healthcare companies with highest earnings beats
Seeking Alpha · 3d ago
What Incyte (INCY)'s Expanded Opzelura EU Approval Means For Shareholders
Simply Wall St · 5d ago
Weekly Report: what happened at INCY last week (0803-0807)?
Weekly Report · 5d ago
More
About INCY
Incyte Corporation is a biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics. It operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise consists of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. It also includes VGA039, a novel monoclonal antibody in Phase III development for von Willebrand disease (VWD). It manages business activities through the development and commercialization of oncology and dermatology products.

Webull offers Incyte Corp stock information, including NASDAQ: INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.